1/9
07:03 pm
rytm
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones [Yahoo! Finance]
1/9
10:58 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Needham & Company LLC from $145.00 to $148.00. They now have a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Needham & Company LLC from $145.00 to $148.00. They now have a "buy" rating on the stock.
1/9
08:00 am
rytm
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
Low
Report
Rhythm Pharmaceuticals Announces Preliminary, Unaudited Fourth Quarter and Full Year 2025 Net Product Revenues and Upcoming Milestones
1/6
02:26 pm
rytm
Invesco Health Care Fund Q3 2025 Commentary [Seeking Alpha]
Low
Report
Invesco Health Care Fund Q3 2025 Commentary [Seeking Alpha]
12/22
07:18 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at HC Wainwright.
12/17
08:44 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at UBS Group AG.
12/17
07:06 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at Guggenheim.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at Guggenheim.
12/12
11:33 am
rytm
Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says [Yahoo! Finance]
Low
Report
Rhythm Pharmaceuticals Phase 2 Setmelanotide Data Show 'Encouraging' Early Activity, Morgan Stanley Says [Yahoo! Finance]
12/12
10:01 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) was given a new $141.00 price target on by analysts at Canaccord Genuity Group Inc..
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) was given a new $141.00 price target on by analysts at Canaccord Genuity Group Inc..
12/12
08:44 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
Medium
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at The Goldman Sachs Group, Inc..
12/12
08:18 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Citizens Jmp from $141.00 to $167.00. They now have a "market outperform" rating on the stock.
Medium
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Citizens Jmp from $141.00 to $167.00. They now have a "market outperform" rating on the stock.
12/12
06:03 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
Medium
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "outperform" rating reaffirmed by analysts at Citigroup Inc..
12/12
04:39 am
rytm
Rhythm Pharmaceuticals (RYTM): Reassessing Valuation After Positive Prader-Willi Data and Phase 3 Trial Plans [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals (RYTM): Reassessing Valuation After Positive Prader-Willi Data and Phase 3 Trial Plans [Yahoo! Finance]
12/12
02:34 am
rytm
Is It Too Late to Invest in Rhythm Pharmaceuticals After Its 2025 Rally? [Yahoo! Finance]
Medium
Report
Is It Too Late to Invest in Rhythm Pharmaceuticals After Its 2025 Rally? [Yahoo! Finance]
12/11
05:04 pm
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at Cowen Inc.
Medium
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" rating reaffirmed by analysts at Cowen Inc.
12/11
04:30 pm
rytm
Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster [Seeking Alpha]
Medium
Report
Rhythm: PWS Signal, HO Speed Bump, And The Case For A Rare-Obesity Blockbuster [Seeking Alpha]
12/11
04:02 pm
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
Medium
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "overweight" rating reaffirmed by analysts at Morgan Stanley.
12/11
03:54 pm
rytm
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript [Seeking Alpha]
Low
Report
Rhythm Pharmaceuticals, Inc. (RYTM) Discusses Preliminary Phase II Data of Setmelanotide in Prader-Willi Syndrome and Next Steps Transcript [Seeking Alpha]
12/11
02:13 pm
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Needham & Company LLC from $120.00 to $145.00. They now have a "buy" rating on the stock.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target raised by analysts at Needham & Company LLC from $120.00 to $145.00. They now have a "buy" rating on the stock.
12/11
08:06 am
rytm
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome [Yahoo! Finance]
High
Report
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome [Yahoo! Finance]
12/11
07:30 am
rytm
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
High
Report
Rhythm Pharmaceuticals Announces Preliminary Data from Exploratory Phase 2 Trial that showed Setmelanotide Demonstrated Positive Efficacy Signal in Prader-Willi Syndrome
12/10
04:11 pm
rytm
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome [Yahoo! Finance]
Medium
Report
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome [Yahoo! Finance]
12/10
04:01 pm
rytm
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
High
Report
Rhythm Pharmaceuticals to Announce Preliminary Data from Exploratory Phase 2 Trial Evaluating Setmelanotide in Prader-Willi Syndrome
11/27
06:19 am
rytm
Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
Low
Report
Rhythm Pharmaceuticals (NASDAQ:RYTM) was upgraded by analysts at Citigroup Inc. to a "strong-buy" rating.
11/25
05:35 pm
rytm
Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress [Seeking Alpha]
Low
Report
Rhythm: Maintaining Strong Buy On Acquired Hypothalamic Obesity Drug Progress [Seeking Alpha]